Literature DB >> 1657463

Low dose streptozotocin causes stimulation of the immune system and of anti-islet cytotoxicity in mice.

G Kantwerk-Funke1, V Burkart, H Kolb.   

Abstract

Multiple low doses of streptozotocin are known to induce immune-mediated insulin deficient diabetes and depression of immune reactivity. We show here that immune depression by streptozotocin is not general but that some parts of the immune system are stimulated. Spleen cells from streptozotocin-treated mice showed enhanced cytotoxicity against syngeneic islet cells and various tumour cells including insulinoma cells. Several cell types served as effector cells, including macrophages, asialo GM1+ and Lyt-2+ lymphocytes. The increased cytotoxic activity towards islet cells was mostly due to macrophages and to non-asialo GM1+ and non-Lyt-2+ lymphocytes. A higher activation state of macrophages in low dose streptozotocin-treated mice was demonstrated by measurements of superoxide anion release. We conclude that multiple low doses of streptozotocin stimulate 'natural cytotoxicity', i.e. the non-MHC restricted cytotoxic activity of macrophages, T cells and natural killer lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657463      PMCID: PMC1554113          DOI: 10.1111/j.1365-2249.1991.tb05808.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  Complete protection from low-dose streptozotocin-induced diabetes in mice.

Authors:  A A Rossini; R M Williams; M C Appel; A A Like
Journal:  Nature       Date:  1978-11-09       Impact factor: 49.962

2.  Immune responses of diabetic animals. Direct immunosuppressant effects of streptozotocin in mice.

Authors:  W K Nichols; J B Spellman; L L Vann; R A Daynes
Journal:  Diabetologia       Date:  1979-01       Impact factor: 10.122

3.  L3T4 and Lyt-2 T cells are both involved in the generation of low-dose streptozotocin-induced diabetes in mice.

Authors:  G Kantwerk; S Cobbold; H Waldmann; H Kolb
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

4.  Administration of silica or monoclonal antibody to Thy-1 prevents low-dose streptozotocin-induced diabetes in mice.

Authors:  M Oschilewski; E Schwab; U Kiesel; U Opitz; K Stünkel; V Kolb-Bachofen; H Kolb
Journal:  Immunol Lett       Date:  1986-06       Impact factor: 3.685

5.  Assessment of the diabetogenic drugs alloxan and streptozotocin as models for the study of immune defects in diabetic mice.

Authors:  G N Gaulton; J L Schwartz; D D Eardley
Journal:  Diabetologia       Date:  1985-10       Impact factor: 10.122

Review 6.  Mouse models of insulin dependent diabetes: low-dose streptozocin-induced diabetes and nonobese diabetic (NOD) mice.

Authors:  H Kolb
Journal:  Diabetes Metab Rev       Date:  1987-07

7.  Multiple low-dose streptozotocin-induced diabetes in the mouse: further evidence for involvement of an anti-B cell cytotoxic cellular auto-immune response.

Authors:  R C McEvoy; N M Thomas; C Hellerström; F Ginsberg-Fellner; T M Moran
Journal:  Diabetologia       Date:  1987-04       Impact factor: 10.122

8.  Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus.

Authors:  A A Like; A A Rossini
Journal:  Science       Date:  1976-07-30       Impact factor: 47.728

9.  Multiple low dose streptozotocin induces systemic MHC expression in mice by triggering T cells to release IFN-gamma.

Authors:  S M Cockfield; V Ramassar; J Urmson; P F Halloran
Journal:  J Immunol       Date:  1989-02-15       Impact factor: 5.422

10.  Induced and spontaneous diabetes mellitus and suppression of cell-mediated immunologic responses. Granuloma formation, delayed dermal reactivity and allograft rejection.

Authors:  A A Mahmoud; H M Rodman; M A Mandel; K S Warren
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

View more
  6 in total

1.  Pancreatic β-Cell production of CXCR3 ligands precedes diabetes onset.

Authors:  Susan J Burke; Michael D Karlstad; Adrianna E Eder; Kellie M Regal; Danhong Lu; David H Burk; J Jason Collier
Journal:  Biofactors       Date:  2016-06-21       Impact factor: 6.113

2.  Circulating monocytes are activated in newly diagnosed type 1 diabetes mellitus patients.

Authors:  K Josefsen; H Nielsen; S Lorentzen; P Damsbo; K Buschard
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

3.  In vivo activation of the PI3K-Akt pathway in mouse beta cells by the EGFR mutation L858R protects against diabetes.

Authors:  Elina Hakonen; Jarkko Ustinov; Décio L Eizirik; Hannu Sariola; Päivi J Miettinen; Timo Otonkoski
Journal:  Diabetologia       Date:  2014-02-04       Impact factor: 10.122

4.  Blood-stage malaria infection in diabetic mice.

Authors:  K Elased; J B De Souza; J H Playfair
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

5.  Interleukin-21 receptor-mediated signals control autoreactive T cell infiltration in pancreatic islets.

Authors:  Tom L Van Belle; Stefan Nierkens; Ramon Arens; Matthias G von Herrath
Journal:  Immunity       Date:  2012-05-10       Impact factor: 31.745

6.  Efficacy of glucagon-like peptide-1 and estrogen dual agonist in pancreatic islets protection and pre-clinical models of insulin-deficient diabetes.

Authors:  Taylor Fuselier; Paula Mota de Sa; M M Fahd Qadir; Beibei Xu; Camille Allard; Mathew M Meyers; Joseph P Tiano; Bin S Yang; Vasily Gelfanov; Sarah H Lindsey; Richard D Dimarchi; Franck Mauvais-Jarvis
Journal:  Cell Rep Med       Date:  2022-04-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.